Aetna, Merck in value-based deal for diabetes drugs

Aetna Inc. (NYSE:AET) and Merck & Co. Inc. (NYSE:MRK) signed a value-based contract covering diabetes drugs Januvia sitagliptin and Janumet sitagliptin/metformin.

Aetna spokesperson Caryn Marshall said that under the multiyear contract, the insurer will analyze claims data to determine whether Type II diabetics are achieving treatment goals or require further therapy, as determined by their physicians. She said Merck will provide rebates if targets are not met, but declined to disclose details on the contract, which is effective Jan. 1. ...